Cellgram-DC (autologous dendritic cell) / Pharmicell - LARVOL DELTA

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Pharmicell Co., Ltd. | N=10 ➔ 2 | Trial completion date: Dec 2022 ➔ May 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ May 2022; Difficult recruitment

Enrollment change • Immune cell • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Ovarian Cancer • Solid Tumor • BRCA • IL12A

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Pharmicell Co., Ltd. | N=10 ➔ 3 | Trial completion date: Dec 2022 ➔ Feb 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Feb 2022; Difficult recruitment

Enrollment change • Immune cell • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST • IL12A

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Pharmicell Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Dec 2020 ➔ Nov 2021

Clinical • Enrollment open • IO biomarker • Trial initiation date • Oncology • Ovarian Cancer • Solid Tumor • BRCA • IL12A

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Pharmicell Co., Ltd.

Clinical • IO Biomarker • New P1 trial • Oncology • Ovarian Cancer • Solid Tumor

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Pharmicell Co., Ltd.

Clinical • IO Biomarker • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor